Gamida Cell Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Abigail L. Jenkins
- Full Time Employees
- 143
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5 Nahum Heftsadie Street Jerusalem Israel 91340
- IPO Date
- Oct 26, 2018
- CIK
- 0001600847
- Website
- gamida-cell.com
- Similar Companies
- Business
- Gamida Cell Ltd. is a biopharmaceutical company focused on developing and commercializing advanced cell therapies for severe hematologic malignancies and other serious diseases. The company leverages its proprietary nicotinamide (NAM)-enabled cell expansion technology to enhance and broaden the therapeutic potential of various cell types, including stem cells and natural killer (NK) cells. Its flagship product, Omisirge (omidubicel-onlv), received U.S. FDA approval in April 2023. This allogeneic cell therapy is indicated for adult and pediatric patients aged 12 and older with blood cancers undergoing umbilical cord blood transplantation, designed to reduce the time to neutrophil recovery and the incidence of infection. Omisirge offers a critical solution for patients struggling to find suitable donors, potentially increasing access to life-saving transplants, particularly for diverse patient populations. In its development pipeline, Gamida Cell continues to advance GDA-201, an innate NK cell immunotherapy, which is currently in an ongoing Phase 1/2 clinical study for patients with non-Hodgkin lymphoma. Earlier preclinical NK cell programs, including GDA-301, GDA-501, and GDA-601, were discontinued in March 2023 as part of a strategic restructuring to prioritize the commercialization of Omisirge. Facing financial constraints, the company commenced a restructuring process in March 2024, supported by its principal lender, Highbridge Capital Management. This initiative includes Gamida Cell transitioning into a private entity wholly owned by Highbridge, with existing public shares expected to be canceled, aimed at securing long-term financial stability to support Omisirge's commercialization. In May 2024, the company filed for Chapter 11 bankruptcy in the U.S. to implement these restructuring transactions. Gamida Cell's operations are now consolidated in Kiryat Gat, Israel.
Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell Actively Pursuing Strategic Alternatives
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
Gamida Cell Ltd. (GMDA) Q3 2023 Earnings Call Transcript
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Gamida Cell to Report Third Quarter 2023 Financial Results
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
Gamida Cell Issues Update on Israel Operations
These Israeli pharmaceutical stocks are down in the wake of Hamas attack